Being patient: what delays access to new drugs in Europe?
On average, the first citizen to access a new drug in Belgium will wait 13 months longer for it than someone prescribed the same drug in Germany or the UK, despite an EU-wide licensing process. This suggests that country-specific drug regulation—the ‘fourth hurdle’ faced by drug manufacturers—may go a long way to explaining launch delay across Europe.
Related
Economics of the Data Act: part 1
As electronic sensors, processing power and storage have become cheaper, a growing number of connected IoT (internet of things) devices are collecting and processing data in our homes and businesses. The purpose of the EU’s Data Act is to define the rights to access and use data generated by… Read More
Adding value with a portfolio approach to funding reduction
Budgets for capital projects are coming under pressure as funding is not being maintained in real price terms. The response from portfolio managers has been to cancel or postpone future projects or slow the pace of ongoing projects. If this is undertaken on an individual project level, it could lead… Read More